

DIPARTIMENTO DI SCIENZE CHIMICHE, DELLA VITA E DELLA SOSTENIBILITÀ AMBIENTALE

CORSO DI LAUREA MAGISTRALE IN SCIENZE BIOMOLECOLARI GENOMICHE E CELLULARI

SERCA-Ca²⁺ Modulation Impairs Glucocorticoid Resistance in *NOTCH1*-Mutated T-Cell Acute Lymphoblastic Leukemia

Laureanda: Costanza Salvatori

Relatore: Prof. Giovanni Roti

Anno accademico 2021/2022

T-Cell Acute Lymphoblastic Leukemia (T-ALL)

- T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic tumor resulting from the malignant transformation of T cell progenitors
- High tumour burden with uncontrolled clonal expansion of malignant lymphoid cells
- It counts for 10–15% of paediatric and 25% of adult acute lymphoblastic leukemia (ALL) cases
- NOTCH1 mutations are observed in 40% to 70% of childhood and adult T-cell acute lymphoblastic leukemia (T-ALL)



The Notch1 Pathway





P-Type ATPase-SERCA and NOTCH1



SERCA and **NOTCH1**



SERCA Inhibitors Thapsigargin, CPA





Thapsigargin

LIMITATIONS

Unmodified TG is difficult to administer and deliver systemically without significant nonspecific host toxicity (cardiac toxicity).

•

•

SOLUTIONS

- Improve TG delivery (tumor specificity):
- Antibody-based strategy
- Folic acid endocytosis strategy



Roti et al. 2018, JEM

- TG-induced inhibition of SERCA leads to depletion of the ER Ca²⁺ pool. Activates plasma membrane calcium channels, thereby resulting in an influx of extracellular calcium.
- Generate isoform specific SERCA inhibitors

CAD204520



Marchesini et al. 2020, Cell Chem Biol

CAD204520 Anti-NOTCH1 Mutated Leukemia Specific Effects









5.64%

150K



Generation of ATP2A2^{mut} T-ALL Model



Intersecting a Chemotranscriptomic Screens to Anticipate SERCA Resistance in T-ALL



RNAseq Identifies Different Transcriptomic Profiles



ATP2A2 Mutation Induces Upregulation of Steroid Metabolism



Transcription Factor Analysis Confirm a Role of Sterol Regulation

4

0

-4





EU-OPENSCREEN Identifies Different Sensitivity Profiles



- Small molecule library screening in TG-sensitive and resistant cell line (ALL/SIL and ALL/SIL R)
- The screening library is part of the European Chemical Biology Library (ECBL)
- 2464 bioactive compounds screened
- The compounds are active against 1039 different targets (654 approved drugs and 368 highly selective probes from the public domain).
- Pathway coverage: cellular response to stress, Immune System, Signal Transduction, Developmental Biology, Gene Expression (Transcription), Hemostasis, Metabolism of proteins, Cell Cycle, Neuronal System

EU-OPENSCREEN Identifies Different Sensitivity Profiles



- Small molecule library screening in TG-sensitive and resistant cell line (ALL/SIL and ALL/SIL R)
- The screening library is part of the European Chemical Biology Library (ECBL)
- 2464 bioactive compounds screened
- The compounds are active against 1039 different targets (654 approved drugs and 368 highly selective probes from the public domain).
- Pathway coverage: cellular response to stress, Immune System, Signal Transduction, Developmental Biology, Gene Expression (Transcription), Hemostasis, Metabolism of proteins, Cell Cycle, Neuronal System

EU-OPENSCREEN Identifies Different Sensitivity Profiles



- Small molecule library screening in TG-sensitive and resistant cell line (ALL/SIL and ALL/SIL R)
- The screening library is part of the European Chemical Biology Library (ECBL)
- 2464 bioactive compounds screened
- The compounds are active against 1039 different targets (654 approved drugs and 368 highly selective probes from the public domain).
- Pathway coverage: cellular response to stress, Immune System, Signal Transduction, Developmental Biology, Gene Expression (Transcription), Hemostasis, Metabolism of proteins, Cell Cycle, Neuronal System

Glucocorticoids are a Specific Active Class in SERCA^{mut} T-ALL





ATP2A2 Mutation Induces Glucocorticoid Sensitivity





New Thapsigargin-Resistant Cell Line



Glucocorticoids Synergize with SERCA Inhibitors *in vitro*





Genes Expression Distinguishes Specific T-ALL Subtypes







HOXA NKX2-1/NKX2-1 MEF2C BCL11B-a Cancer Cells 2002 (1) 75,87 Cancer Cell 2011, (4) 484-497 Blood 2005 (106), 274-286 Blood 2017;129:1113-1123 Blood. 2021 Sep 2;138(9):773-784

Activation

TAL/LMO

TLX1

TLX3

SERCA^{mut} Cell Line Clusters with TAL/LMO Genetic Subgroup



SERCA^{mut} Cell Line Clusters with TAL/LMO Genetic Subgroup





	Patient	Sex	Phenotype	CI-FISH	IC50 (μM) / AUC		
					CAD	Dex	CAD+Dex
	BM-117-2021	Μ	Early	STIL::TAL1 CDKN2AB bDEL CASP8AP2- GRIK2-SEC63- FYN del NF1-SUZ12 gain TP53 DEL	8.59 365	NR 295	0.85 263
	BM-122-2021	Μ	Early	SIL::TAL1 NF1 del SUZ2 del	5.59 343	0.27 215	0.06 189
	BM-015-2021	М	Mature	TRAD::LMO2 CDKN2AB del GRIK2- CASP8AP2- SEC63-FYN del TP53 mDEL	1.58 304	NR 350	1.94 290
	BM-066-2022	F	Pro-T/ETP	TRAD::LMO2; LEF1 del; iso(17q)/TP53del	4.01 336	0.03 165	0.02 153

Conclusions

- Prolonged administration of TG induces the rising of mutations at the ligand binding site (LBD)
- As long as ATP2A2^{mut} and wt cell line are syngenic, the LBD mutation induces transcriptomic modifications and generate sensitivity to glucocorticoids
- SERCA inhibition synergize with glucocorticoids in *ATP2A2^{mut}* cell lines
- The R cell lines shows a gene expression profile that is similar to the gene expression pattern of TAL1 T-ALL genotypic subgroup
- The dissection of metabolic pathways could help to define the relationship between SERCA and glucocorticoid metabolism

Acknowledgements

- Giovanni Roti, M.D., Ph.D.
- Luca Pagliaro
- Anna Montanaro
- Federica Vento
- Elisa Cerretani
- Elisa Simoncini
- Anna D'Antuono
- Andrea Gherli
- Lucas Moron Dalla Tor
- Raffaella Zamponi
- Maria Teresa Giaimo
- Bruno Lorusso
- Alessia Ciringione



